Gynecologic Cancers

Carcinoma of the cervix is one of the most common malignancies in women, accounting for 15,700 new cases and 4,900 deaths in the United States each year. Worldwide, cervical cancer is second only to breast cancer as the most common

VIENNA--A new study from the EORTC Gynecologic Cancer Cooperative Group (GCCG) has challenged the assumption that aggressive combination chemotherapy is worthwhile in chemotherapy-naïve women with metastatic squamous cell cancer of the cervix.

A total of 18 studies have been published concerning the possible relationship of tamoxifen to endometrial

For women diagnosed with stage I cervical cancer during pregnancy who are torn between the desire to maintain a healthy pregnancy and the need for cancer treatment, a recent study offers hope that both desires can be achieved. The study,

WASHINGTON--For the first time since its inception in 1991, funds from the Breast and Cervical Cancer Early Detection Program will flow to all 50 states in fiscal 1997, the Department of Health and Human Services announced.

An expert panel of nine international cancer researchers and practicing oncologists met in Boston to discuss the past, present, and future uses of antiestrogens in the treatment of breast cancer. The first article in this series, based on the symposium presentations, focused on the optimal duration of tamoxifen use (October 1996). This month, the panel explores the noncancer benefits of tamoxifen, as well as the potential risk of endometrial cancer. The symposium was sponsored by Zeneca Pharmaceuticals.

In their comprehensive review of changing concepts in the management of endometrial cancer, Drs. Karasek and Faul highlight the contemporary approach to the management of patients with endometrial adenocarcinoma. The authors stress the evolution

The authors present the major issues and controversies surrounding the treatment of endometrial cancer. A variety of therapeutic approaches have been used in the past, including surgery alone, preoperative radiation and surgery, surgery and

Endometrial carcinoma was a clinically staged disease until the late 1980s, at which point, staging changed to a surgicopathologically defined system. This change in staging, in turn, altered the clinical management of this

NEW ORLEANS--In a phase I trial from M.D. Anderson Cancer Center, the chemopreventive agent difluorometh-ylornithine (DFMO) produced significant regression of cervical intraepithelial neoplasia (CIN) grade 3, Michele Follen Mitchell, MD, reported at the Society of Gynecologic Oncologists meeting.

Cervical cancer's slow, noticeable growth makes it "an ideal disease" for screening, but poor choices--like not getting a Pap smear or having unprotected sex as young adults--give the disease a disastrous head start, a University of Wisconsin Medical

SEATTLE-A group of breast cancer patients treated with tamoxifen (Nolvadex) outside of clinical trials had up to a 60% reduction in their risk of developing cancer in the contralateral breast and no increased risk of ovarian or endometrial cancer, report Linda S. Cook, PhD, and her colleagues at the Fred Hutchinson Cancer Research Center.

Ten-year survival data of patients with high-risk cervical cancer emphasize the need for extended-field irradiation, according to

The April 1995 issue of Oncology featured an article that presented sound information on the state of viral interactions and cervical cancer, along with several excellent reviews. Cancer of the uterine cervix is a significant health and emotional

Bacterial vaginosis, the most widespread vaginal infection in the United States, is associated with a 357% increase in the incidence of cervical intraepithelial neoplasia (CIN), an abnormality of cervical

Tamoxifen (Nolvadex), a nonsteroidal antiestrogen, was first approved by the FDA for the treatment of patients with breast cancer in 1978. Large clinical trials have demonstrated a recurrence-free and overall survival benefit

In his excellent review, Dr. Barakat has made many useful observations about the effects of tamoxifen (Nolvadex) on the endometrium. As the potential number of women on tamoxifen increases, several points merit emphasis and dissemination to all gynecologists who may be asked by medical oncologists to render opinions on such patients.

Tamoxifen (Nolvadex) is widely used in the treatment of breast cancer. It is effective in the management of both early stage and advanced disease. The recent comprehensive meta-analysis of systemic treatment in early breast cancer reported that tamoxifen reduced the annual odds of breast cancer recurrence by 25%, and the risk of death by 16%, compared with patients not treated with tamoxifen [1]. The benefits are even more pronounced in postmenopausal patients, with 29% decreases in recurrence and 20% reduction in the risk of death. The risk of contralateral primary breast cancer is also decreased by approximately 28% in women receiving adjuvant tamoxifen [2]. This has prompted its use in prevention trials; the National Surgical Adjuvant Breast and Bowel Project Prevention trial (NSABP P1) is an ongoing trial randomizing women at high risk for breast cancer to receive tamoxifen or placebo. Tamoxifen's use in otherwise healthy women has brought attention to the few potential toxicities of the drug.